Brief: Idera Pharma Announces Immuno-Oncology Clinical Research Collaboration With Abbvie

Aceragen

04/09/2019 12:26

Sept 4 (Reuters) - Idera Pharmaceuticals Inc  IDRA.O :
    * IDERA PHARMACEUTICALS ANNOUNCES IMMUNO-ONCOLOGY CLINICAL
RESEARCH COLLABORATION WITH ABBVIE
    * IDERA PHARMACEUTICALS INC - ENTERED INTO AN
IMMUNO-ONCOLOGY
CLINICAL RESEARCH COLLABORATION WITH ABBVIE
    * IDERA PHARMACEUTICALS INC - PHASE 1B TO DETERMINE SAFETY
OF
COMBINATIONS OF ABBV-368 PLUS TILSOTOLIMOD IN SUBJECTS WITH
RECURRENT OR METASTATIC HNSCC
    * IDERA PHARMACEUTICALS INC - STUDY WILL TEST THREE SEPARATE
TREATMENT ARMS
    * IDERA PHARMACEUTICALS INC - IDERA WILL PROVIDE CLINICAL
TRIAL
SUPPLY OF TILSOTOLIMOD TO ABBVIE AND ABBVIE WILL BE RESPONSIBLE
FOR CONDUCT OF STUDY

Source text for Eikon:  ID:nGNX1KQdlQ 
Further company coverage:  IDRA.O 

 (Reuters.Briefs@thomsonreuters.com)